A hybrid technique of intracavitary and interstitial brachytherapy for locally advanced cervical cancer: initial outcomes of a single-institute experience

Table 3 Potential predictors influencing local control (LC), progression-free survival (PFS), and overall survival (OS)

	2-y LC (%)		LC		2-y PFS (%)		PFS		2-y OS (%)		OS
	yes (n)	no (n)	p value in uni.	p value in multi.	yes	no	p value in uni.	p value in multi.	yes	no	p value in uni.	p value in multi.
Scc vs Non-Scc	86.0 (40)	50 (2)	0.101		54.6 (40)	50 (2)	0.967		79.9 (40)	100 (2)	0.669
LN+	89.5 (20)	78.8 (22)	0.878		40.0 (20)	67.5 (22)	0.052		73.5 (20)	84.5 (22)	0.448
Initial tumor size > 6 cm	73.2 (21)	95.2 (21)	0.042^*		33.3 (21)	75.9 (21)	0.005^*	p = 0.043, HR 0.333, 95%CI 0.115–0.965	75.3 (21)	85.0 (21)	0.037^*
Ulceration plus corpus invasion	56.4 (15)	96.3 (27)	0.006^*	p = 0.017, HR 0.123, 95%CI 0.22–0.689	26.7 (15)	70.0 (27)	0.002^*	p = 0.027, HR 0.340, 95%CI 0.131–0.882	46.7 (15)	96.2 (27)	0.001^*	p = 0.003, HR 0.118, 95%CI 0.029–0.482
Hydronephrosis	77.1 (10)	87.1 (32)	0.960		50.0 (10)	56.1 (32)	0.981		88.9 (10)	76.9 (32)	0.316
Pyometra	91.7 (12)	81.4 (30)	0.433		50.0 (12)	56.3 (30)	0.554		68.8 (12)	84.1 (30)	0.972
Combination of weekly CDDP	80.3 (28)	92.3 (14)	0.706		56.9 (28)	49.0 (14)	0.917		81.8 (28)	76.6 (14)	0.968
HR-CTV at initial BT > 40 ml	71.2 (19)	95.5 (23)	0.032^*		36.8 (19)	69.1 (23)	0.026^*		74.2 (19)	86.7 (23)	0.297
HR-CTV D₉₀ > 70 Gy	85.2 (24)	83.0 (18)	0.888		45.5 (24)	66.7 (18)	0.156		83.5 (24)	76.2 (18)	0.820
CTV-Corpus V₁₀₀ > 99%	100 (13)	73.4 (29)	0.062		59.8 (13)	51.7 (29)	0.457		83.9 (13)	76.8 (29)	0.412
Mean HR-CTV V₂₀₀ > 34%	100 (14)	76.4 (28)	0.042^*		55.6 (14)	53.6 (28)	0.699		85.1 (14)	77.2 (28)	0.396

PFS progression-free survival, OS overall survival, uni.: univariate analysis, multi.: multivariate analysis, LN+ regional lymph node positive, HR-CTV high risk clinical target volume, BT brachytherapy, HR-CTV D₉₀ minimum dose covering 90% of the HR-CTV, HR-CTV V₂₀₀ the percentage of the HR-CTV receiving higher than 200% of the prescribed dose

ISSN: 1471-2407